Psychedelic Research Group, Centre for Psychiatry, Division of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK.
University of Oxford Department of Psychiatry and Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK.
Neuropsychopharmacology. 2017 Oct;42(11):2105-2113. doi: 10.1038/npp.2017.84. Epub 2017 Apr 26.
Plant-based psychedelics, such as psilocybin, have an ancient history of medicinal use. After the first English language report on LSD in 1950, psychedelics enjoyed a short-lived relationship with psychology and psychiatry. Used most notably as aids to psychotherapy for the treatment of mood disorders and alcohol dependence, drugs such as LSD showed initial therapeutic promise before prohibitive legislature in the mid-1960s effectively ended all major psychedelic research programs. Since the early 1990s, there has been a steady revival of human psychedelic research: last year saw reports on the first modern brain imaging study with LSD and three separate clinical trials of psilocybin for depressive symptoms. In this circumspective piece, RLC-H and GMG share their opinions on the promises and pitfalls of renewed psychedelic research, with a focus on the development of psilocybin as a treatment for depression.
植物源致幻剂,如裸盖菇素,具有悠久的药用历史。1950 年首次在英文文献中报道 LSD 后,迷幻剂与心理学和精神病学短暂地建立了联系。在 20 世纪 60 年代中期,LSD 等药物作为辅助心理治疗情绪障碍和酒精依赖的手段被广泛使用,在具有抑制性的立法之前,这些药物显示出了初步的治疗前景,随后所有主要的迷幻剂研究项目都被有效地终止了。自 20 世纪 90 年代初以来,人类迷幻剂研究一直在稳步复兴:去年,人们报告了首次使用 LSD 进行的现代脑成像研究,以及三项单独的用裸盖菇素治疗抑郁症状的临床试验。在这篇回顾性文章中,RLC-H 和 GMG 就重新开展迷幻剂研究的前景和陷阱分享了他们的看法,重点讨论了将裸盖菇素开发为一种治疗抑郁症的方法。